isomalt

HCT pharmacokinetic parameters (Cmax, tmax, t1/2, AUC0-24 h)

no effect, p = 0.05

were not significantly different (P>0.05; two-way ANOVA) in comparison with the conventional tablet

PMID:12270622 · one of two readings recorded this

hydrochlorothiazide plasma Cmax, tmax, t1/2, AUC(0-24 h) from isomalt-based moulded tablets versus conventional tablet (isomalt is the tablet matrix, not the dosed drug)

no effect, pharmacokinetic parameters not significantly different from conventional tablet

Not recorded as a finding: the comparison was against another active treatment

Moulded tablets had a high relative bioavailability (F(rel)) as the pharmacokinetic parameters (C(max), t(max), t(1/2), AUC(0-->24 h)) determined from HCT plasma concentration versus time profiles were not significantly different (P>0.05; two-way ANOVA) in comparison with the conventional tablet.

PMID:12270622 · one of two readings recorded this

hydrochlorothiazide plasma Cmax, tmax, t1/2, AUC(0-24h) and relative bioavailability from isomalt-based moulded tablets versus a conventional tablet

no effect, PK parameters not significantly different from conventional tablet

Not recorded as a finding: the comparison was against another active treatment

Moulded tablets had a high relative bioavailability (F(rel)) as the pharmacokinetic parameters (C(max), t(max), t(1/2), AUC(0-->24 h)) determined from HCT plasma concentration versus time profiles were not significantly different (P>0.05; two-way ANOVA) in comparison with the conventional tablet.

PMID:12270622 · one of two readings recorded this

relative bioavailability of HCT

no effect

The relative bioavailability of the moulded tablet administered as a lozenge and as an oral tablet was 106.2+/-30.9% and 89.4+/-25.9%, respectively, in relation to the conventional tablet formulation

PMID:12270622 · one of two readings recorded this

relative bioavailability of HCT

no effect

The relative bioavailability of the moulded tablet administered as a lozenge and as an oral tablet was 106.2+/-30.9% and 89.4+/-25.9%, respectively, in relation to the conventional tablet formulation

PMID:12270622 · one of two readings recorded this

stool frequency

increases, p = 0.006

Stool frequency was moderately increased in the isomalt phase (P=0.006)

PMID:16197583 · one of two readings recorded this

apolipoprotein A-1

decreases, p = 0.03

apart from lower apo A-1 (P=0.03) for all subjects

PMID:16197583 · one of two readings recorded this

blood lipids

no effect

Blood lipids were comparable in both phases, especially in volunteers with hyperlipidaemia

PMID:16197583 · one of two readings recorded this

calcium and phosphate homeostasis (urine and stool excretion)

no effect

Ca and phosphate homeostasis was not affected

PMID:16197583 · one of two readings recorded this

remnant-like particles, oxidised LDL, NEFA, fructosamine and leptin

no effect

Remnant-like particles, oxidised LDL, NEFA, fructosamine and leptin were comparable and not influenced by isomalt

PMID:16197583 · one of two readings recorded this

stool consistency and stool water

no effect

without changes in stool consistency and stool water

PMID:16197583 · one of two readings recorded this

stool frequency, blood lipids, urinary and stool Ca and phosphate, mean transit time in healthy volunteers

increases, stool frequency moderately increased in the isomalt phase, p = 0.006, n = 19

Not recorded as a finding: the comparison was against another active treatment

Stool frequency was moderately increased in the isomalt phase (P=0.006) without changes in stool consistency and stool water.

PMID:16197583 · one of two readings recorded this

stool frequency, stool consistency, blood lipids, apo A-1, Ca and phosphate excretion

increases, Stool frequency was moderately increased in the isomalt phase, p = 0.006

Not recorded as a finding: the comparison was against another active treatment

Stool frequency was moderately increased in the isomalt phase (P=0.006) without changes in stool consistency and stool water.

PMID:16197583 · one of two readings recorded this

enamel de- and remineralization

decreases

continuous presence of 10% Isomalt (in re- or demineralizing solutions) inhibited both de- and/or remineralization

PMID:18157558 · one of two readings recorded this

enamel remineralization

increases

while 5-min rinses with 10% Isomalt gave slightly increased remineralization, continuous presence of 10% Isomalt (in re- or demineralizing solutions) inhibited both de- and/or remineralization

PMID:18157558 · one of two readings recorded this

enamel remineralization

increases

In in situ study, remineralization enhancement during short Isomalt treatments was confirmed

PMID:18157558 · one of two readings recorded this

overall mineral loss

decreases

This lead to significantly smaller overall mineral loss when Isomalt was added during demineralization

PMID:18157558 · one of two readings recorded this

isomalt production yield via enzymatic conversion of isomaltulose

increases

From HPLC analysis it was showed for the first time that the enzyme could convert substrate isomaltulose to the specific products, GPM and GPS.

PMID:19266906 · one of two readings recorded this

mannitol dehydrogenase specific enzymatic activity with fructose as substrate

63 U mg-1 protein

Results from activity assay with fructose as substrate also showed that in this strain the specific activity of 63 U mg(-1) protein monitored for the enzyme, the record not reported before.

PMID:19266906 · one of two readings recorded this

MDH enzyme expression level across E. coli strains

increases

The results showed that among the strains, BL21 (DE3) plysS exhibited the maximum expression level of MDH(mannitol dehydrogenase) (11 mg L(-1)).

PMID:19266906 · one of two readings recorded this

MDH substrate specificity and conversion of isomaltulose to GPM and GPS by HPLC

increases

From HPLC analysis it was showed for the first time that the enzyme could convert substrate isomaltulose to the specific products, GPM and GPS.

PMID:19266906 · one of two readings recorded this

amorphous-state retention during storage

no effect

All powders remained amorphous during 2-3 weeks.

PMID:27321131 · one of two readings recorded this

glass transition temperature and processability (stickiness)

decreases

Isomalt was the most problematic, because it had the lowest Tg and became sticky very easily, therefore process parameters needed to be precisely balanced.

PMID:27321131 · one of two readings recorded this

solid-state stability of spray-dried amorphous isomalt as a protein-stabilizing pharmaceutical excipient (amorphous-state retention, glass transition temperature, powder stickiness), compared to sucrose, trehalose and melibiose

decreases

Not recorded as a finding: the compound was a reagent, not an exposure

Isomalt was the most problematic, because it had the lowest Tg and became sticky very easily, therefore process parameters needed to be precisely balanced.

PMID:27321131 · one of two readings recorded this

spray-drying yield and solid-state stability of amorphous isomalt powder

Isomalt was the most problematic, because it had the lowest Tg and became sticky very easily, therefore process parameters needed to be precisely balanced.

PMID:27321131 · one of two readings recorded this

dissolution rate of celecoxib in 0.25% SDS and 0.04M Na3PO4 dissolution media

increases

Similar results have been shown for dissolution studies.

PMID:28024614 · one of two readings recorded this

dissolution rate of celecoxib in solid dispersion

increases

Similar results have been shown for dissolution studies.

PMID:28024614 · one of two readings recorded this

saturation solubility and dissolution rate of celecoxib formulated as a spray-dried solid dispersion with Isomalt and PVP K30 as hydrophilic carriers

increases, 20-30 folds higher saturation solubility than raw celecoxib

Not recorded as a finding: the compound was a reagent, not an exposure

The results showed that the saturation solubility of celecoxib in solid dispersion samples is 20-30 folds higher than raw celecoxib.

PMID:28024614 · one of two readings recorded this

saturation solubility and dissolution rate of celecoxib in isomalt/PVP K30 solid dispersion formulations

increases, 20-30 fold higher saturation solubility than raw celecoxib

Not recorded as a finding: the compound was a reagent, not an exposure

The results showed that the saturation solubility of celecoxib in solid dispersion samples is 20-30 folds higher than raw celecoxib.

PMID:28024614 · one of two readings recorded this

saturation solubility of celecoxib in isomalt/PVP solid dispersions

increases, 20-30 fold higher saturation solubility than raw celecoxib

The results showed that the saturation solubility of celecoxib in solid dispersion samples is 20-30 folds higher than raw celecoxib.

PMID:28024614 · one of two readings recorded this

saturation solubility of celecoxib

increases, 20-30 folds higher saturation solubility than raw celecoxib

The results showed that the saturation solubility of celecoxib in solid dispersion samples is 20-30 folds higher than raw celecoxib.

PMID:28024614 · one of two readings recorded this

borborygms (mild)

increases, p = 0.01

A reduction in isomalt to 30 g was marked by increased tolerance with evidence of only mild borborygms (P <0.01)

PMID:8617186 · one of two readings recorded this

flatulence, borborygms and colic (mild)

increases, p = 0.01

Ingestion of 40 g maltitol caused less intolerance than 40 g isomalt, with evidence of only flatulence, borborygms and colic (P <0.01)

PMID:8617186 · one of two readings recorded this

flatulence, colic and laxation (mild)

increases, p = 0.05

mild flatulence, colic, and laxation (P <0.05)

PMID:8617186 · one of two readings recorded this

incidence and severity of all GI symptoms (flatulence, borborygms, colic, motion frequency, loose stools)

increases, p = 0.01

The ingestion of 30 g or 40 g lactitol resulted in a significant increase in the incidence and severity of all symptoms examined compared to reactions after the consumption of standard sucrose-containing chocolate (P <0.01)

PMID:8617186 · one of two readings recorded this

incidence and severity of flatulence, borborygms, colic, motion frequency and loose stools after 30 g or 40 g polyol in milk chocolate, self-reported

increases, 40 g isomalt increased incidence of all symptoms including mild laxation versus sucrose chocolate, p = 0.01, n = 59

Not recorded as a finding: the comparison was against another active treatment

Similarly, 40 g isomalt led to an increased incidence of all symptoms, including mild laxation (P <0.01), but unlike lactitol none was rated as being severe.

PMID:8617186 · one of two readings recorded this

incidence and severity of flatulence, borborygms, colic, motion frequency and loose stools after isomalt, lactitol or maltitol in milk chocolate versus sucrose chocolate

increases, 40 g isomalt increased incidence of all symptoms including mild laxation versus sucrose chocolate, p = 0.01, n = 59

Not recorded as a finding: the comparison was against another active treatment

Similarly, 40 g isomalt led to an increased incidence of all symptoms, including mild laxation (P <0.01), but unlike lactitol none was rated as being severe.

PMID:8617186 · one of two readings recorded this

incidence of all GI symptoms including mild laxation

increases, p = 0.01

40 g isomalt led to an increased incidence of all symptoms, including mild laxation (P <0.01)

PMID:8617186 · one of two readings recorded this

laxative effect

no effect, p = 0.32

Maltitol did not have any laxative effect when ingested at either 30 g (P = 0.32) or 40 g (P = 0.13) per day

PMID:8617186 · one of two readings recorded this

laxative effect

no effect, p = 0.13

Maltitol did not have any laxative effect when ingested at either 30 g (P = 0.32) or 40 g (P = 0.13) per day

PMID:8617186 · one of two readings recorded this

motion frequency

no effect, p = 0.35

with no increase in motion frequency (P <0.35)

PMID:8617186 · one of two readings recorded this